by Raynovich Rod | Feb 26, 2024 | 2020-21 Life Science Portfolios, 2023 Rayno Biopharmaceuticals Portfolio, 2023 Rayno Tools and Diagnostics Portfolio
3/1/24…Still plenty of good biotech trades around as XBI recovers over 3% to $101.53. Big movers today were: ABOS, CRMD, DNLI, GERN, IMTX, SUPN. https://www.nasdaq.com/market-activity/etf/xbi/advanced-charting 2/29 at close ..MOmentum is easing with volatility...
by Raynovich Rod | Jan 31, 2024 | 2023 Rayno Biopharmaceuticals Portfolio, 2023 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Update-4. 2/15….2:30p EST XBI pushing for new 52 weeks highs at $93.61. Biotechs/medtechs strong: CRBU, CRMD, CRSP, CPRX, CYRX, ILMN,SUPN, TWST, VCEL. Update-3 2/6..3P EST Some of my SMID caps are coming alive as the XBI ticks up to $89 level: strength among my...
by Raynovich Rod | Dec 26, 2023 | 2020-21 Life Science Portfolios, 2023 Rayno Biopharmaceuticals Portfolio
Update-4 1/3/23-1p EST,…Shift in biopharma toward large cap biotechs. Review small cap trades for profit taking. Our favorite large caps are: ABBV, GILD, LLY, MRK, REGN, VRTX; more speculative picks are BBII and PFE. We will update our Large Cap Biopharma...
by Raynovich Rod | Dec 11, 2023 | 2020-21 Life Science Portfolios, 2023 Rayno Biopharmaceuticals Portfolio
Update-3 12/15 2P EDT. Crazy week so take some profits. Update-2 …12/13/23… Dont fight the tape as momentum rally continues with a little help from the FED. Broad rally takes all indices up over 1.3% with small cap Russell 2000 (IWM) up 3.39%! Biotechs...
by Raynovich Rod | Oct 16, 2023 | 2020-21 Life Science Portfolios, 2023 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 10/20 Merck (MRK) pops over 2% to $102+ on ADC deal with Daiichi Sankyo. Collaboration combines Daiichi Sankyo’s proven ADC expertise and DXd technology with Merck’s deep experience in oncology and clinical development capabilities to advance and expand the...
by Raynovich Rod | Aug 29, 2023 | 2020-21 Life Science Portfolios
Update-1 9/2 Biotechs nudge off bottom with IBB at 3 month high at $130 level. FTC concedes Amgen fight over Horizon deal. XBI finds an uptick of 2.44% to $81 handle on Friday. MedTech still sluggish with IHI in low fifties in choppy trading all year. Novartis joins...
by Raynovich Rod | Jul 17, 2023 | 2020-21 Life Science Portfolios
Update-2 Jy 22 Catch-up Rally last week continues in MedTech and Diagnostics: ABT our top pick up 5.89% to $114.29, DHR up 6.38% to $255.88,IHI up 1.32% to $57.59,TMO up 6.89% to $562. New Pick Becton Dickinson (BDX) up 2.1% to $264.84. Earnings coming next week...
by Raynovich Rod | Jun 21, 2023 | Biopharmaceuticals
Healthcare Stocks Lag but Trading Action is Picking up in Biotech Large Cap Biopharma are core holdings: ABBV, LLY, MRK, REGN, VRTX etc. Healthcare is a laggard with XLV down YTD but UNH is still a core position. Lack of Momentum in SMID caps-XBI is still the key...
by Raynovich Rod | Jun 12, 2023 | 2020-21 Life Science Portfolios, Macro
Update-2 6/18…11 a EDT, Medtech Rally: FSMEX , IHI, ABT, BSX etc. Update-1 2P EDT 6/14…FED day brings volatility and easing of momentum. Don’t fight the tape with small caps weak. XBI is down 2%, Russell 2000 is down 1.65%. We started selling and...
by Raynovich Rod | May 15, 2023 | 2020-21 Life Science Portfolios
Update-2…May 19 1015a in early trading, stocks are opening on the green side. Biopharma stocks are trying to firm up after a spate of weakness from the FTC action on the AMGN/Horizon deal: ABBV, GILD, LLY, REGN, RHHBY MRK, VRTX. Update-1 May 17 …Broad...